Beigene Ltd (BGNE) Sees Unusually-High Trading Volume
Beigene Ltd (NASDAQ:BGNE) saw strong trading volume on Friday . 51,512 shares changed hands during trading, a decline of 1% from the previous session’s volume of 52,232 shares.The stock last traded at $29.01 and had previously closed at $29.39.
A number of equities research analysts have issued reports on the stock. Cowen and Company reaffirmed a “buy” rating on shares of Beigene in a report on Thursday, May 12th. Zacks Investment Research raised shares of Beigene from a “sell” rating to a “hold” rating in a report on Thursday, May 26th. Finally, Morgan Stanley raised their target price on shares of Beigene from $39.00 to $42.00 in a report on Friday, April 8th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Beigene currently has an average rating of “Buy” and a consensus target price of $39.67.
The firm’s 50-day moving average price is $30.01 and its 200-day moving average price is $28.99. The firm’s market capitalization is $668.14 million.
Beigene (NASDAQ:BGNE) last released its earnings results on Wednesday, May 11th. The company reported ($0.97) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.05) by $0.92. The company earned $0.70 million during the quarter. The company’s revenue for the quarter was down 50.0% compared to the same quarter last year. On average, equities research analysts predict that Beigene Ltd will post ($3.17) EPS for the current year.
BeiGene, Ltd. is a biopharmaceutical company. The Company is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. It is developing its product candidate, BGB-3111, a potent and selective small molecule Bruton’s tyrosine kinase (BTK) inhibitor, as a monotherapy and in combination with other therapies for the treatment of a range of lymphomas.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.